Journal article
Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN study)
J Fayette, L Wirth, C Oprean, A Udrea, A Jimeno, D Rischin, C Nutting, PM Harari, T Csoszi, D Cernea, P O'Brien, WD Hanley, AV Kapp, M Anderson, E Penuel, B McCall, A Pirzkall, JB Vermorken
Frontiers in Oncology | FRONTIERS MEDIA SA | Published : 2016
Abstract
Background: Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks ligand binding to epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), inhibits signaling from all ligand-dependent HER dimers, and can elicit antibody-dependent cell-mediated cytotoxicity. High tumor-expression of neuregulin 1 (NRG1), a ligand to HER3, may enhance sensitivity to duligotuzumab. Methods: This multicenter, open-label, randomized phase II study (MEHGAN) evaluated drug efficacy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) progressive on/after chemotherapy and among patients with NRG1-high tumors. Patients r..
View full abstractGrants
Awarded by Cancer Research UK
Funding Acknowledgements
This work was supported by Genentech, Inc., South San Francisco, CA, USA. CN was supported by Cancer Research UK Programme Grant A13407 and the RM/ICR NIHR Biomedical Research Centre.